Syensqo's Role in Oligonucleotide Synthesis
The face of medicine is changing with new techniques focused on prevention, rather than correction, of life-threatening diseases. Modern therapies enable doctors to block disease-causing errors in a patient’s generic code without changing it. Syensqo's high-purity, safely scaleable phos reagent is used in the synthesis of oligonucleotides, the building blocks for RNA- / DNA- based drugs used in today's treatments. Phos reagent is a vital intermediate in the manufacture of one class of treatments known as antisense drugs.
Antisense drugs work by blocking harmful messenger RNA and, therefore, prevent the formation of disease-causing proteins. They are used in multiple clinical trials designed to address genetic diseases such as Huntington’s, Crohn’s and breast cancer.
Syensqo's phos reagents, the same materials used in oligonucleotide synthesis, also support the development of a newer class of drugs known as synthetic small interfering RNAs (siRNAs) that utilize phosphoramidite monomers. Researchers are investigating double-stranded RNA molecules designed to act via RNA interference pathways. siRNAs are used to prevent the production of specific disease-causing proteins with targets including cancer, HIV infection and hepatitis.
Facilitating Phosphoramidite Monomer Production
RhodaPhos® Phos Reagent, Syensqo's pharmaceutical intermediate, is used primarily in the manufacture of antisense oligonucleotides. The product enables the formation of phosphoramidite monomers, which in turn are used to create the synthetic RNA required for antisense therapy. Benefits of choosing Syensqo for phosphoramidite synthesis include:
- Scalability: Syensqo's unique operational process occurs in large reactors and is built for immediate scale-up, enabling more reliable, safer process scale-up to multiton levels.
- Superior storage potential: A stable product, RhodaPhos® Phos Reagent offers a long shelf life and flexibility in storage conditions as there is no need for storage at low temperatures, thus eliminating the need for specialized, dedicated storage space.
- Less waste and greater efficiency: Syensqo's innovative manufacturing process starts and ends clean, with a sustained purity level of > 99%, which equates to minimal waste, efficient production and cost optimization.
- Flexible solutions: The technical agility of our R&I and technical support teams helps us adapt to the evolving purity requirements for cyanoethyl phosphoramidites and develop the appropriate packaging formats for the RhodaPhos® Phos Reagent to allow straightforward handling without risk of facility contamination.
Stringent Control Over Phos Reagent Impurities
Syensqo has a comprehensive understanding of the source of impurities in cyanoethyl phosphoramidite and has elucidated the structure of many of them. Our ability to stringently control the presence of specific impurities minimizes amplification during amidite and oligonucleotide synthesis ౼ a clear benefit to customers in the oligonucleotide synthesis supply chain. Furthermore, our high-purity solutions help customers avoid subsequent toxicological tests designed to eliminate adverse effects in the final drug product.
